|
Cogentin (Benztropine mesylate)
|
|
Central nervous system agent
|
|
Antiparkinson agent
|
|
As an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders except tardive dyskinesia
|
|
Usually 1 to 2 mg/day. Range 0.5 to 6 mg/day before or after meal.
|
|
Category C
|
|
Fast heart beats, Constipation, vomiting, nausea, dry mouth, confusion, disorientation, memory impairement, visual hallucinations, nervousness, Depression, Blurred Vision, dilated pupils, skin rash.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
|
|
|